The level of melatonin is decreased in serum of mice with diabetes-accelerated atherosclerosis, and exogenous supplement of melatonin reduces iNOS expression and S-nitrosylation of GNAI2, thus alleviating diabetes-accelerated atherosclerosis. Here, GNAI2 is linked to atherosclerosis.